share_log

Ascendiant Capital Initiates Coverage On Cyclo Therapeutics With Buy Rating, Announces Price Target of $2.6

Moomoo 24/7 ·  Apr 22 05:40

Ascendiant Capital analyst Lucas Ward initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rating and announces Price Target of $2.6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment